We are live on ! Find out more
0.6391 USD
+0.0091
1.44%
At close Updated Sep 25, 12:23 PM EDT
1 day
1.44%
5 days
-3.46%
1 month
-10.74%
3 months
-45.84%
6 months
-51.95%
Year to date
-45.38%
1 year
-42.42%
5 years
-91.61%
10 years
-95.52%
 

About: IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

Employees: 108

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 80%
Negative 20%
Negative
Zacks Investment Research
1 month ago
IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%
IRIX's Q2 loss per share widens year over year and revenues decline as Middle East disruptions and reduced sell-through in China weigh on retina sales, offsetting continued growth in the Cyclo G6 product family.
IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%
Neutral
Seeking Alpha
1 month ago
IRIDEX Corporation (IRIX) Q2 2026 Earnings Call Transcript
IRIDEX Corporation (IRIX) Q2 2026 Earnings Call Transcript
IRIDEX Corporation (IRIX) Q2 2026 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Iridex Reports Second Quarter 2026 Financial Results
MOUNTAIN VIEW, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 4, 2026.
Iridex Reports Second Quarter 2026 Financial Results
Neutral
GlobeNewsWire
1 month ago
Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026
MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the second quarter 2026 and provide a business update after the close of trading on August 18, 2026.
Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026
Neutral
GlobeNewsWire
2 months ago
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
MOUNTAIN VIEW, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the expansion of its EyeProGPO product offering to include the Company's line of EndoProbe® Handpieces.
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
Neutral
GlobeNewsWire
3 months ago
Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
MOUNTAIN VIEW, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming Planet MicroCap Las Vegas 2026 Conference.
Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
Negative
Zacks Investment Research
4 months ago
IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth
IRIDEX posts a narrower year-over-year net loss per share in Q1'26 as strong glaucoma product sales and lower operating costs helped offset weakness in retina sales and supply-chain disruptions.
IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth
Neutral
Seeking Alpha
4 months ago
IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript
IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript
IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript
Neutral
GlobeNewsWire
4 months ago
Iridex Reports First Quarter 2026 Financial Results
MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 4, 2026.
Iridex Reports First Quarter 2026 Financial Results
Neutral
GlobeNewsWire
4 months ago
Iridex to Report First Quarter 2026 Financial Results on May 19, 2026
MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the first quarter 2026 and provide a business update after the close of trading on May 19, 2026.
Iridex to Report First Quarter 2026 Financial Results on May 19, 2026
Price charts implemented using Lightweight Charts™